Abstract: A pharmaceutical formulation comprising a growth hormone and Lys-Gly-Asp-Ser (SEQ ID No: 1) as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formulation at ambient temperature.

Abstract: The present invention relates to insulin crystals comprising ASP.sup.B28 and protamine, and pharmaceutical preparations containing same. The crystals and preparations exhibit rapid onset and prolonged activity when administered in vivo.

Abstract: A pharmaceutical formulation comprising a growth hormone and valine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formulation at ambient temperature.

Abstract: The present invention relates to a novel method for treating a mammal suffering from gastrointestinal motility disorders.

Abstract: A manually operated dispenser for dispensing a predetermined amount of powdered substance comprises a pressure cylinder (2) with an axially displaceable piston (3). A super-atmospheric pressure is generated by displacing the piston inwardly in the cylinder and is releaved through a chamber (41) in a magazine (40) comprising a number of chambers (41) containing powdered substance. The ends of the chambers (41) are covered by penetrable membranes (48), and the chambers (41) may be moved to successively being in alignment with a penetrator (30) and an outlet pipe (46). When the piston (3) is in its inner-most position the penetrator (30) and the inlet end of the out-let pipe (46) are forced through the respective membranes (48) at the ends of the chamber (41), and the subatmospheric pressure is releaved through the chamber (41) to dispense its content through the outlet pipe (46).

Abstract: A coagulation active complex of Factor VIII fragments is produced by causing a coagulation inactive FVIII heavy chain to react with a coagulation inactive FVIII light chain in the presence of a complex forming agent. Thus, FVIII-HC and FVIII-LC are converted to coagulation active FVIII complex in the presence of metal ions, such as Mn.sup.2+, Ca.sup.2+, or Co.sup.2+ or a component of the prothrombin complex or a substance having reactivity to compounds containing the group --SH and/or --S--S.

Abstract: A process for the preparation of a peroxycarboxylic acid of general formula (I), wherein R is an organic residue, in particular a linear or branched alkyled group, an aryl group or an alkyl aryl group each of which is optionally substituted with one or more groups, the process comprising treating a carboxylic acid of the general formula R--COOH, wherein R has the meaning indicated above, with hydrogen peroxide or a precursor thereof in the presence of an enzyme catalyst is described. The enzyme catalyst is preferably a hydrolase, such as a protease or a lipase. Also, a process for the oxidation of organic compounds with the peroxycarboxylic acids thus prepared is described.

Abstract: The present invention relates to rhamnogalacturonases derived from a strain of Aspergillus japonicus which (a) has a pH-optimum between 6.5 and 7.0; (b) retains at least 80% of the maximal activity throughout the pH range of 5.5-12; (c) has a temperature optimum of about 40.degree. C.; and (d) retains at least 80% of the maximal activity throughout the temperature range of 20.degree.-60.degree. C. The present invention relates to rhamnogalacturonases derived from a stain of Aspergillus aculeatus which (a) has a pH-optimum of about 5.0; (b) retains at least 80% of the maximal activity throughout the pH range of 3-6.5; (c) has a temperature optimum of about 40.degree. C.; and (d) retains at least 80% of the maximal activity throughout the temperature range of 5.degree.-50.degree. C.

Abstract: A combination of GnRH analog, gonadotrophins, and growth hormone is very useful for treating infertility in higher mammals and humans since the probability of pregnancy is enhanced and the total doses of gonadotrophins are reduced. The treatment is initiated with administration of GnRH analog and continued with administration of gonadotrophins and growth hormone.

Abstract: The present invention relates to therapeutically active heterocyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system related to the metabotropic glutamate receptor system.

Abstract: A process for expression of a protein product in Aspergillus oryzae is disclosed. The process comprises transforming Aspergillus oryzae with a vector system comprising DNA-sequences encoding functions facilitating gene expression, a suitable marker for selection of transformants, and a DNA-sequence encoding the desired protein product. The process enables industrial production of many different polypeptides and proteins in A. oryzae. Examples of such products are chymosin or prochymosin and other rennets, proteases, lipases and amylases. Also disclosed is an effective promoter for expression of a protein in Aspergillus. A preferred promoter is the TAKA-amylase promoter or functional parts thereof. There is also provided a process for the production of a recombinant Humicola lipase. The recombinant Humicola lipase from A. oryzae differs from the native lipase in having a greater glycosylation and in exhibiting an improved thermostability.

Abstract: The present invention relates to therapeutically active azacyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.

Abstract: The invention relates to a process for converting peroxycarboxylic acids to carboxylic acids, the process comprising treating a peroxycarboxylic acid of the general formula I:R--CO--OOH (I)wherein R is a linear or branched alkyl group, an aryl group or an aryl-alkyl group each of which may optionally be substituted with one or more hydroxy, halogen, alkoxy, amino, alkylamino, sulfo, sulfoxy, sulfono, amido, carboxy, percarboxy or nitro groups, with an enzyme catalyst to form the corresponding carboxylic acid of the general formula II:R--CO--OH (II)wherein R has the meaning indicated above.

Abstract: The method comprises a series of steps, with raw meat as a starting material, including a hydrolysis with a specified neutral and alkaline protease. The meat hydrolyzate exhibits excellent organoleptic properties and can be used as a flavoring additive to a soup concentrate.

Abstract: The present invention relates to [1,2,4]triazolo[4,3-a quinoxaline derivatives of formula I ##STR1## wherein one of R.sup.1 and R.sup.2 is a 5- or 6-membered nitrogen-containing heterocyclic ring which is optionally substituted with one, two or three substituents, wherein each substituent is independently phenyl or C.sub.1-6 -alkyl, or one of R.sup.1 and R.sup.2 is a fused ring system comprising a 5- or 6-membered nitrogen-containing heterocyclic ring and a benzene, pyridine, pyrimidine or pyrazine ring, wherein the fused ring system is optionally substituted with phenyl or C.sub.1-6 -alkyl; and the other of R.sup.1 and R.sup.2 is hydrogen, C.sub.1-6 -alkyl, C.sub.1-6 -alkoxy, halogen, NO.sub.2, NH.sub.2, CN, CF.sub.3, COC.sub.1-6 -alkyl or SO.sub.2 NR'R", wherein R' and R" are independently hydrogen or C.sub.1-6 -alkyl; and X is O or S; and pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to proteases obtained from a strain of Bacillus sp. PD138, detergent additives and compositions comprising a Bacillus sp. PD138 protease, and methods of making and using a Bacillus sp. PD138 protease.

Abstract: In the method for casein finishing of leather, transglutaminase is added to a casein solution, whereafter the thus formed solution is applied to leather, which is dried. Transglutaminase, which is not toxic, functions as a hardening agent in the method.

Abstract: The present invention relates to therapeutically active azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.

Abstract: The invention relates to a detergent composition comprising a protease and one or more other enzymes, as well as comprising a reversible protease inhibitor of the peptide or protein type.

Abstract: The invention is directed to a method for deinking and uncoating printed paper which comprises using a monocomponent cellulase during recycling.